Survival analysis of patients with different sub-stages of Barcelona clinic liver cancer classification stage B hepatocellular carcinoma after TACE / 中国介入影像与治疗学

ABSTRACT

Objective: To investigate the necessity of sub-classification for Barcelona clinic liver cancer (BCLC) classification stage B hepatocellular carcinoma (HCC), and to analyze the curative effect and survival of patients with different substages HCC after TACE. Methods: Clinical and follow-up data of 133 patients with BCLC classification stage B HCC treated with TACE were retrospectively analyzed. There were 31 cases of substage B1, 77 of substage B2, 15 of substage B3 and 10 cases of substage B4. The curative effect and survival of patients were evaluated. Results: Totally 567 times of TACE treatments were performed on 133 patients. There was no statistical difference of the TACE treatment times among patients with different substages (F=1.702, P=0.170). One month after the first time TACE, partial response was achieved in 47 cases, while stable disease and progressive disease were found in 74 cases and 12 cases respectively according to modified response evaluation criteria in solid tumors criteria. No statistical difference of curative effect was detected among patients with different substages (χ2=2.121, P=0.908). The overall survival of patients with different substages HCC after TACE was statistically different (χ2=10.846, P=0.013). The survival time of patients with substage B1 was significantly longer than that of patients with substage B3 (P=0.020) and B4 (P=0.033), respectively. Conclusion: The overall survival of patients with BCLC classification stage B HCC after TACE are different. This sub-classification is beneficial for clinic to formulate specific treatment plan.